Payment overview · 2025
General Payments
$422.86
21 reported records · 10 companies
Healthcare provider profile · identity verified
Kenneth E Mcclure, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LONGVIEW, TX · NPI 1770550311
Verified facts
What the public records show
CMS Open Payments records show Kenneth E Mcclure, MD received $422.86 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 30.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 416 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $130.49 | 30.9% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.49 | 17.4% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $63.01 | 14.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.67 | 9.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.55 | 5.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.77 | 5.4% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $19.65 | 4.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.92 | 4.2% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $16.51 | 3.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.80 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $422.86 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $130.49 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $111.39 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $73.49 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $73.49 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.67 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.00 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $30.01 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 416 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
416 | 70 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 842 | 214 |
| Amlodipine Besylate | Amlodipine Besylate | 674 | 162 |
| Losartan Potassium | Losartan Potassium | 674 | 147 |
| Pantoprazole Sodium | Pantoprazole Sodium | 654 | 167 |
| Potassium Chloride | Potassium Chloride | 582 | 139 |
| Gabapentin | Gabapentin | 551 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 507 | 140 |
| Furosemide | Furosemide | 471 | 122 |
| Metformin Hcl | Metformin Hcl | 464 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 454 | 118 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 447 | 83 |
| Lisinopril | Lisinopril | 444 | 114 |
| Eliquis | Apixaban | 416 | 70 |
| Alprazolam | Alprazolam | 369 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 329 | 97 |
| Trazodone Hcl | Trazodone Hcl | 308 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 303 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 291 | 78 |
| Meloxicam | Meloxicam | 277 | 56 |
| Hydralazine Hcl | Hydralazine Hcl | 267 | 55 |
| Omeprazole | Omeprazole | 263 | 78 |
| Duloxetine Hcl | Duloxetine Hcl | 256 | 53 |
| Divalproex Sodium | Divalproex Sodium | 252 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 239 | 74 |
| Mirtazapine | Mirtazapine | 236 | 54 |
| Tramadol Hcl | Tramadol Hcl | 235 | 57 |
| Montelukast Sodium | Montelukast Sodium | 221 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 220 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 51 |
| Carvedilol | Carvedilol | 218 | 58 |
| Levetiracetam | Levetiracetam | 201 | 33 |
| Famotidine | Famotidine | 197 | 45 |
| Simvastatin | Simvastatin | 193 | 57 |
| Pregabalin | Pregabalin | 191 | 38 |
| Glimepiride | Glimepiride | 187 | 35 |
| Sertraline Hcl | Sertraline Hcl | 186 | 42 |
| Allopurinol | Allopurinol | 182 | 44 |
| Temazepam | Temazepam | 174 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 53 |
| Venlafaxine Hcl | Venlafaxine Hcl | 165 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 160 | 40 |
| Memantine Hcl | Memantine Hcl | 157 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 143 | 28 |
| Clonazepam | Clonazepam | 141 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 136 | 34 |
| Donepezil Hcl | Donepezil Hcl | 132 | 33 |
| Bupropion Xl | Bupropion Hcl | 130 | 26 |
| Lorazepam | Lorazepam | 128 | 25 |
| Diazepam | Diazepam | 127 | 23 |
| Jardiance | Empagliflozin | 122 | 22 |
| Januvia | Sitagliptin Phosphate | 112 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 108 | 23 |
| Finasteride | Finasteride | 107 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 41 |
| Alendronate Sodium | Alendronate Sodium | 102 | 25 |
| Baclofen | Baclofen | 102 | 17 |
| Atenolol | Atenolol | 101 | 24 |
| Ozempic | Semaglutide | 101 | 15 |
| Methocarbamol | Methocarbamol | 97 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 95 | 24 |
| Methylprednisolone | Methylprednisolone | 90 | 72 |
| Buspirone Hcl | Buspirone Hcl | 88 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 87 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 23 |
| Levofloxacin | Levofloxacin | 84 | 63 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 83 | 19 |
| Nifedipine Er | Nifedipine | 81 | 23 |
| Xarelto | Rivaroxaban | 80 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 17 |
| Clonidine Hcl | Clonidine Hcl | 78 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 18 |
| Myrbetriq | Mirabegron | 76 | suppressed |
| Prednisone | Prednisone | 76 | 32 |
| Spironolactone | Spironolactone | 75 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 73 | 26 |
| Azithromycin | Azithromycin | 67 | 59 |
| Nitroglycerin | Nitroglycerin | 66 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 16 |
| Torsemide | Torsemide | 61 | 21 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 60 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 19 |
| Topiramate | Topiramate | 59 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 16 |
| Celecoxib | Celecoxib | 54 | 14 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Sucralfate | Sucralfate | 54 | 15 |
| Entresto | Sacubitril/Valsartan | 53 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 16 |
| Risperidone | Risperidone | 53 | suppressed |
| Aripiprazole | Aripiprazole | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 18 |
| Metformin Hcl Er | Metformin Hcl | 51 | suppressed |
| Primidone | Primidone | 50 | suppressed |
| Cefdinir | Cefdinir | 49 | 37 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | suppressed |
| Ondansetron Odt | Ondansetron | 49 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | 16 |
| Fenofibrate | Fenofibrate | 46 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 13 |
| Propranolol Hcl | Propranolol Hcl | 46 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 45 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | 11 |
| Enalapril Maleate | Enalapril Maleate | 44 | suppressed |
| Ezetimibe | Ezetimibe | 42 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 41 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 32 |
| Glipizide | Glipizide | 40 | 16 |
| Lovastatin | Lovastatin | 40 | 11 |
| Midodrine Hcl | Midodrine Hcl | 40 | 13 |
| Latanoprost | Latanoprost | 39 | 12 |
| Digoxin | Digoxin | 38 | suppressed |
| Fluconazole | Fluconazole | 38 | 19 |
| Olanzapine | Olanzapine | 38 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 38 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Telmisartan | Telmisartan | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 15 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | 11 |
| Nystatin | Nystatin | 36 | 22 |
| Cephalexin | Cephalexin | 35 | 26 |
| Meclizine Hcl | Meclizine Hcl | 35 | 11 |
| Fenofibrate | Fenofibrate,micronized | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | 13 |
| Estradiol | Estradiol | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 31 | suppressed |
| Galantamine Er | Galantamine Hbr | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 29 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 29 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Metolazone | Metolazone | 29 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 26 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Acetylcysteine | Acetylcysteine | 25 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 13 |
| Ramipril | Ramipril | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 19 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 18 |
| Lithium Carbonate | Lithium Carbonate | 22 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Sulfasalazine | Sulfasalazine | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 19 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Nystop | Nystatin | 16 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Metaxalone | Metaxalone | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Valproic Acid | Valproic Acid | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 13 |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Probenecid | Probenecid | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $422.86 · 21 records | Novo Nordisk Inc | Auvelity, CeQur Simplicity, ELIQUIS, INSPIRE, Kerendia, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error